400 related articles for article (PubMed ID: 26578727)
21. [Vismodegib in metastasized basal cell carcinoma].
Reinders MG; Dirix L; Mosterd K; van Doorn R
Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
[TBL] [Abstract][Full Text] [Related]
22. Basal Cell Carcinoma: A Comprehensive Review.
Dika E; Scarfì F; Ferracin M; Broseghini E; Marcelli E; Bortolani B; Campione E; Riefolo M; Ricci C; Lambertini M
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759706
[TBL] [Abstract][Full Text] [Related]
23. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
24. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report.
Awad R; Andrade JCB; Mousa H; Mahmoud F
Perm J; 2018; 22():17-181. PubMed ID: 30005721
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
26. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
Dubey AK; Dubey S; Handu SS; Qazi MA
J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
[TBL] [Abstract][Full Text] [Related]
27. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
[TBL] [Abstract][Full Text] [Related]
28. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
29. Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma.
Fosko SW; Chu MB; Mattox AR; Richart JM; Burkemper NM; Slutsky JB
Dermatol Ther; 2015; 28(6):359-62. PubMed ID: 26114264
[TBL] [Abstract][Full Text] [Related]
30. Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib.
Sternfeld A; Rosenwasser-Weiss S; Ben-Yehuda G; Shefer HK; Friedman-Gohas M; Yassur I; Tauber G; Bejar J; Olshinka A; Vardizer Y; Ad El D; Goldenberg-Cohen N
Sci Rep; 2020 Jan; 10(1):1244. PubMed ID: 31988301
[TBL] [Abstract][Full Text] [Related]
31. Advanced treatment for basal cell carcinomas.
Atwood SX; Whitson RJ; Oro AE
Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
[TBL] [Abstract][Full Text] [Related]
32. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
Lyons TG; O'Kane GM; Kelly CM
Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
[TBL] [Abstract][Full Text] [Related]
34. Metastatic spinal cord compression from basal cell carcinoma of the skin treated with surgical decompression and vismodegib: case report and review of Hedgehog signalling pathway inhibition in advanced basal cell carcinoma.
McGrane J; Carswell S; Talbot T
Clin Exp Dermatol; 2017 Jan; 42(1):80-83. PubMed ID: 27905158
[TBL] [Abstract][Full Text] [Related]
35. The Role of Surgery After Remission of Nonsystemic Extensive Periorbital Basal Cell Carcinoma Treated by Vismodegib: A Systematic Review.
Peillex D; Passemard L; Magnin B; Rouanet J; Pham Dang N
Dermatol Surg; 2022 Sep; 48(9):905-911. PubMed ID: 36054041
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
37. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
[No Abstract] [Full Text] [Related]
38. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
39. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.
Fife D; Laitinen MA; Myers DJ; Landsteiner PB
Pediatr Dermatol; 2017 Mar; 34(2):163-165. PubMed ID: 28297142
[TBL] [Abstract][Full Text] [Related]
40. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL
JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
